Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

Eli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat ...

NVO's first-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially ...

New Delhi: Torrent Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the Phase III clinical ...

Ozempic isn't FDA approved to help with weight loss, but other drugs containing GLP-1 receptor agonists - like semaglutide (Wegovy ... There is a GLP-1 pill on the market now called Rybelsus, however ...

That came in response to a February lawsuit from a compounding trade group against the Food and Drug Administration's determination that the active ingredient in those drugs, semaglutide ...

"We are deeply disappointed that the (court) misapprehended or failed to take into consideration the clear and convincing evidence that demonstrates that the manufactured supply of semaglutide is ...

70. Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug semaglutide, sold under the brand names Ozempic and Wegovy.

A federal judge April 24 rejected a bid by compounding pharmacies to continue selling less expensive copies of semaglutide, Novo Nordisk's blockbuster drug sold under the brands Wegovy and Ozempic.

Novo Nordisk sells semaglutide under the brands Wegovy and Ozempic for weight loss and type 2 diabetes treatment respectively. Image credit: Getty/UCG. A US judge has rejected efforts by a compounded ...